Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$20.04 -2.9%	$19.22	$15.47 ▼ $36.37	$685.63M	1.47	184,018 shs	302,038 shs
KOD Kodiak Sciences	$3.50 -2.2%	$3.31	$1.92 ▼ $11.60	$184.67M	2.42	347,208 shs	173,413 shs
PHAR Pharming Group	$10.28 -4.8%	$8.87	$6.65 ▼ $11.07	$699.36M	-0.08	6,458 shs	903 shs
RCKT Rocket Pharmaceuticals	$2.48 +6.4%	$6.44	$2.19 ▼ $26.98	$264.83M	1.02	1.81 million shs	20.90 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-2.86%	-2.10%	-4.21%	-15.44%	+5.64%
KOD Kodiak Sciences	-2.23%	-1.13%	-16.86%	-12.72%	+16.67%
PHAR Pharming Group	-4.68%	-2.00%	+17.49%	+20.37%	+13.59%
RCKT Rocket Pharmaceuticals	+6.44%	-62.37%	-65.36%	-73.62%	-88.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.1622 of 5 stars	3.6	0.0	0.0	2.8	0.0	0.0
KOD Kodiak Sciences	4.0902 of 5 stars	3.0	3.0	4.6	1.8	3.3	0.6
PHAR Pharming Group	2.4993 of 5 stars	3.5	5.0	0.0	2.1	0.0	0.6
RCKT Rocket Pharmaceuticals	4.7869 of 5 stars	4.2	2.0	4.7	2.0	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	96.04% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	157.14% Upside
PHAR Pharming Group	3.00	Buy	$30.00	191.83% Upside
RCKT Rocket Pharmaceuticals	2.47	Hold	$22.46	805.71% Upside

Current Analyst Ratings Breakdown

Latest KOD, PHAR, AVBP, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/28/2025	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	RCKT Rocket Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$5.07 per share	N/A
PHAR Pharming Group	$320.71M	2.18	$0.11 per share	91.82	$3.26 per share	3.15
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
KOD Kodiak Sciences	-$260.49M	-$3.63	N/A	N/A	N/A	N/A	-84.52%	-45.40%	8/13/2025 (Estimated)
PHAR Pharming Group	-$10.55M	-$0.20	N/A	342.67	N/A	-6.09%	-7.65%	-3.82%	7/30/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest KOD, PHAR, AVBP, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A
3/13/2025	Q4 2024	PHAR Pharming Group	$0.07	$0.05	-$0.02	$0.05	$76.67 million	$92.70 million
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
KOD Kodiak Sciences	N/A	8.42	8.42
PHAR Pharming Group	0.41	3.53	2.76
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
KOD Kodiak Sciences	89.06%
PHAR Pharming Group	0.03%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
KOD Kodiak Sciences	45.30%
PHAR Pharming Group	2.07%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
KOD Kodiak Sciences	90	52.76 million	28.79 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

KOD, PHAR, AVBP, and RCKT Headlines

Recent News About These Companies

Rocket Pharmaceuticals' (RCKT) Hold Rating Reiterated at Needham & Company LLC

May 29 at 1:37 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from Brokerages

May 29 at 1:34 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

May 28 at 6:25 PM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect

May 28 at 3:15 PM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Hold" at TD Cowen

May 28 at 12:18 PM | marketbeat.com

RCKT Stock Tanks on Patient Death in Danon Disease Study

May 28 at 12:11 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by Needham & Company LLC

May 28 at 11:29 AM | marketbeat.com

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

May 28 at 10:41 AM | benzinga.com

Rocket Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RCKT)

May 28 at 10:38 AM | marketbeat.com

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease

May 28 at 5:39 AM | pharmabiz.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Hold" Rating from TD Cowen

May 28 at 2:41 AM | americanbankingnews.com

Investors Purchase High Volume of Rocket Pharmaceuticals Call Options (NASDAQ:RCKT)

May 28 at 1:06 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

May 27 at 9:28 PM | insidermonkey.com

Danon Disease Patient Dies in Rocket Gene Therapy Trial

May 27 at 7:37 PM | genengnews.com

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

May 27 at 12:00 PM | benzinga.com

Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death

May 27 at 10:37 AM | proactiveinvestors.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.6% - Time to Sell?

May 25, 2025 | marketbeat.com

Woodline Partners LP Increases Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 25, 2025 | marketbeat.com

Toronto Dominion Bank Purchases Shares of 1,100,000 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 22, 2025 | marketbeat.com

271,659 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Soleus Capital Management L.P.

May 21, 2025 | marketbeat.com

Northern Trust Corp Has $8.34 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
By Leo Miller | May 22, 2025
View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
By Leo Miller | May 6, 2025
View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

KOD, PHAR, AVBP, and RCKT Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$20.04 -0.59 (-2.86%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$20.04 0.00 (0.00%)

As of 05/28/2025 04:13 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Kodiak Sciences NASDAQ:KOD

$3.50 -0.08 (-2.23%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.72 +0.22 (+6.40%)

As of 05/28/2025 04:34 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Pharming Group NASDAQ:PHAR

$10.28 -0.52 (-4.81%)

Closing price 05/28/2025 03:21 PM Eastern

Extended Trading

$10.28 0.00 (0.00%)

As of 05/28/2025 04:04 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.48 +0.15 (+6.44%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.49 +0.01 (+0.40%)

As of 05/28/2025 07:59 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time